{"filings":[{"id":860876,"accession_number":"0001193125-26-257376","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-06-04T20:05:17+00:00","items":["2.05","8.01"],"status":"ready","headline":"Fulcrum cuts workforce 85% after SCD drug failure; hires Leerink for strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced from 57 to 9 employees (~85% cut) after discontinuing pociredir for sickle cell disease.","Expects ~$4.2M in restructuring charges (severance, benefits) mostly in Q2 2026.","Engaged Leerink Partners as financial advisor to explore strategic alternatives including merger or sale.","No timeline set for strategic review; no assurance of any transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":777884,"accession_number":"0001193125-26-251394","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-06-01T20:05:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued pociredir for sickle cell disease after FDA feedback; no viable regulatory path forward.","FDA cited secondary malignancy risk from another PRC2 inhibitor (Tazverik) withdrawn March 2026.","Company will explore strategic alternatives (merger, acquisition, etc.) and reduce operating expenses.","Held $333.3M in cash, cash equivalents, and marketable securities as of March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94653,"accession_number":"0001193125-26-178806","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.02","2.02","5.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q1 net loss $18.9M, CFO retiring, CAMP4 license terminated, pociredir trial planned H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CFO Alan Musso retiring; will stay until successor named then consultant through Feb 2027.","Terminated CAMP4 license for Diamond-Blackfan anemia program; no further milestone/royalty payments.","Q1 net loss $18.9M ($17.7M Q1 2025); cash $333.3M, runway into 2029.","Positive pociredir Phase 1b data: HbF induction, hemolysis/anemia improvements; registration-enabling trial H2 2026.","Board appointed Josh Lehrer M.D., independent, receives option for 64,000 shares at $8.08."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107180,"accession_number":"0001193125-26-065190","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.","Fulcrum plans to initiate a potential registration-enabling trial in H2 2026 after FDA End-of-Phase meeting in Q2 2026.","Cash, cash equivalents, and marketable securities of $352.3M as of Dec 31, 2025; cash runway extended into 2029.","Net loss for FY2025 was $74.9M vs $9.7M in FY2024; R&D expenses decreased to $56.1M from $63.4M.","Discontinued bone marrow failure syndrome program; focus on pociredir and benign hematology pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107179,"accession_number":"0001193125-26-009845","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulcrum reports ~$352.3M cash as of Dec 31, 2025; updates presentation for JPM conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of $352.3M as of December 31, 2025.","Updated corporate slide presentation (Exhibit 99.1) issued January 12, 2026, containing business and strategic updates.","Management to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. PT.","Presentation will be webcast live on Fulcrum's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123515,"accession_number":"0001193125-25-314728","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics prices $175M upsized public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten offering of 11,851,853 shares at $13.50/share and pre-funded warrants for 1,111,193 shares at $13.499 each.","Gross proceeds of $175M; net proceeds estimated at $164.1M (or $188.1M if underwriter option exercised).","Offering upsized; underwriters granted 30-day option to purchase up to 1,944,456 additional shares.","Net proceeds to fund general corporate purposes, including R&D, clinical trials, and potential acquisitions.","Closing expected on or about December 11, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123514,"accession_number":"0001193125-25-310509","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Fulcrum reports positive Phase 1b data for pociredir in SCD: 58% patients achieved HbF>=20% at 20 mg dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean absolute HbF increased 9.9% at Week 6 in 20 mg cohort (vs 5.6% in 12 mg); 7 of 12 patients (58%) achieved HbF ≥20%.","Clear dose-response: >3.75-fold mean HbF induction at Week 12 (n=6) vs 2.4-fold in 12 mg cohort.","Hemolysis markers improved at Week 6: indirect bilirubin -37%, LDH -37%, reticulocyte counts -33%.","Pociredir well-tolerated with no treatment-related SAEs or discontinuations; dosed in 148 adults to date.","Plans to submit IND for bone marrow failure syndromes (e.g., Diamond-Blackfan anemia) in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123513,"accession_number":"0001193125-25-254619","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $200.6M; cash runway into 2028.","Net loss $19.6M in Q3 2025 versus $21.7M in Q3 2024; R&D spend $14.3M.","12 mg dose cohort of Phase 1b PIONEER trial showed dose-dependent HbF increase and VOC reduction.","Enrollment completed in 20 mg dose cohort (n=12); data expected by year-end 2025.","Plans to submit IND for bone marrow failure syndromes (DBA, 5q-, etc.) in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140193,"accession_number":"0001193125-25-190746","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics provides updated corporate presentation; no specific new facts disclosed in filing.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made an updated corporate presentation available on its website for investor meetings.","Filing does not contain any new financial results, clinical data, or material operational changes.","Presentation content not fully included in the submission; details are unknown from this filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140192,"accession_number":"0000950170-25-099404","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.","Phase 1b 12 mg cohort: mean HbF increased 8.6% (7.6% to 16.2%); 7/16 patients achieved >20% HbF.","Hemolysis markers improved: indirect bilirubin -37%, LDH -28%, reticulocyte -30%; total hemoglobin +0.9 g/dL.","Safety: pociredir generally well-tolerated, no drug-related SAEs, all treatment-related AEs Grade 1.","20 mg cohort ongoing; data expected by end of 2025; IND for DBA planned Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157835,"accession_number":"0001193125-25-151276","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fulcrum Therapeutics 2025 annual meeting passes director elections, say-on-pay, auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Katina Dorton, Robert Gould, and Kate Haviland elected with 44.6M, 43.8M, and 33.2M votes for, respectively.","Non-binding say-on-pay resolution approved with 46.1M votes for (99.8% of votes cast excluding broker non-votes).","Stockholders selected one year as frequency of future say-on-pay votes (44.9M votes for one year).","Ernst & Young LLP ratified as independent auditor for FY2025 with 49.5M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157834,"accession_number":"0000950170-25-061439","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.","Phase 1b PIONEER trial: enrollment complete for 12mg dose cohort (n=16), 20mg cohort started.","On track to report 12mg cohort data in early Q3 2025 and 20mg cohort data by end of 2025.","R&D expenses fell to $13.4M from $19.8M due to losmapimod discontinuation and Sanofi reimbursement.","Cash runway expected to fund operations into at least 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176217,"accession_number":"0000950170-25-032355","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"MyoKardia terminates Fulcrum collaboration; Fulcrum loses future milestones and royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MyoKardia (BMS unit) terminated the collaboration agreement for convenience; effective June 26, 2025.","Fulcrum forfeits all future milestone payments (up to $298.5M per target), royalties, and research cost reimbursement.","Fulcrum had received $10M upfront, $2.5M prepaid research funding, and achieved a $2.5M preclinical milestone.","Parties will continue obligations until June 26, 2025; no further revenues from the agreement after termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176216,"accession_number":"0000950170-25-026063","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.","Cash and marketable securities $241.0M as of Dec 31, 2024, sufficient into at least 2027.","Phase 1b PIONEER trial of pociredir in SCD: 10 patients enrolled in 12 mg cohort; data expected mid-2025.","Plan to submit IND for Diamond-Blackfan anemia program in Q4 2025.","Phase 3 REACH trial (losmapimod) data to be presented at MDA Conference on March 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":80000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176215,"accession_number":"0001193125-25-004942","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulcrum expects ~$240M cash at year-end 2024 (preliminary)","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Expects approximately $240M in cash, equivalents and marketable securities as of Dec 31, 2024 (preliminary, unaudited).","Full Q4 and FY2024 financial results not yet finalized; audit ongoing.","Updated corporate presentation published on January 13, 2025 on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193105,"accession_number":"0001193125-24-284214","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.","Fulcrum received $80M upfront but forfeits all remaining milestones (up to $975M) and tiered royalties.","Fulcrum no longer entitled to global development cost reimbursement; Phase 3 trial obligations continue until termination.","After termination, Fulcrum retains full rights to losmapimod but loses ex-U.S. partner and future payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193104,"accession_number":"0000950170-24-125927","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.","Cash $257.2M as of Sept 30, 2024, up from $236.2M at Dec 31, 2023, due to $80M Sanofi upfront.","Phase 1b PIONEER trial for pociredir (SCD) advancing; Cohorts 3 (12mg) and 4 (20mg) planned; data expected 2025.","Losmapimod development suspended after Phase 3 REACH failure; company refocuses on pociredir and aplastic anemias.","Cash runway into at least 2027; FY2025 cash burn guided at $55-65M; expects ~$240M cash at end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":80000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193103,"accession_number":"0001193125-24-256101","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director James Collins resigns; Rachel King appointed to board of Fulcrum Therapeutics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James J. Collins resigned as Class II director effective Nov 12, 2024, not due to any disagreement with the company or board.","Board appointed Rachel King as Class II director to fill the vacancy; term expires at 2027 annual meeting.","King is independent and will serve on Compensation & Human Capital Management Committee.","King receives standard non-employee director compensation including option for 60,000 shares at $3.64 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209484,"accession_number":"0000950170-24-109069","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.","One-time severance costs of approximately $2 million expected in Q3 2024.","Annual operating expense savings of about $10 million anticipated starting Q1 2025.","Majority of costs incurred by September 30, 2024; implementation substantially complete by Q3 end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209483,"accession_number":"0001193125-24-217822","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.","All secondary endpoints (MFI, shoulder strength, PROs) did not reach statistical significance.","Fulcrum suspends losmapimod development; safety profile consistent with prior studies.","$273.8M cash as of June 30 used for pociredir (SCD), DBA programs, and early discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209482,"accession_number":"0001193125-24-205347","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics exchanges 9.35M shares for pre-funded warrants with RA Capital and another stockholder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RA Capital exchanged 8,500,000 shares for a pre-funded warrant for 8,500,000 shares at $0.001 exercise price, no expiration.","Another institutional stockholder exchanged 850,000 shares for pre-funded warrants for 850,000 shares on same terms.","Beneficial ownership blocker set at 9.99%; RA Capital can increase to 19.99% with 61 days' notice.","No cash proceeds to Fulcrum; exchange exempt from registration under Section 3(a)(9) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209481,"accession_number":"0000950170-24-088236","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.","Cash and securities $273.8M as of June 30, 2024; expected to fund operations into 2027.","Phase 3 REACH trial (losmapimod for FSHD) topline data expected by end of October 2024; 260 patients enrolled.","Collaboration with Sanofi for ex-U.S. losmapimod; $80M upfront received in Q2.","Phase 1b pociredir (SCD) advancing; cohorts at 12 mg and 20 mg once daily planned."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":80000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227545,"accession_number":"0001193125-24-162653","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Fulcrum expands board to 9, elects Colin Hill; stockholders elect directors, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board expanded from 8 to 9; Colin Hill elected Class I director, term expiring at 2026 annual meeting.","Hill received automatic grant of 60,000 nonqualified stock options at $7.00/share.","Annual meeting: James Collins, James Geraghty, Alex Sapir elected as Class II directors for 3-year term.","Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227544,"accession_number":"0000950170-24-058187","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Fulcrum signs $80M upfront Sanofi deal for losmapimod ex-U.S.; Q1 net loss $26.9M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sanofi pays $80M upfront; Fulcrum eligible for up to $975M in milestones and tiered low-teens to mid-twenties royalties on ex-U.S. sales.","Cash, equivalents, and securities $213.3M at March 31; pro forma ~$293.3M including Sanofi upfront; runway into 2027.","Net loss $26.9M for Q1 2024 vs $24.8M in Q1 2023; R&D expenses $19.8M due to REACH trial advancement.","Phase 3 REACH trial for losmapimod in FSHD on track to report topline data in Q4 2024.","Appointed Patrick Horn, M.D., Ph.D., as CMO; Phase 1b pociredir trial in sickle cell disease expanding to cohorts 3 and 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}